Purple biotech announces first patient dosed in open label, randomized part of cm24 phase 2 clinical trial

Rehovot, israel, feb. 14, 2023 (globe newswire) -- purple biotech ltd. (“purple biotech” or “the company”) (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that the first patient has been dosed in the randomized part of the open label phase 2 clinical trial evaluating cm24 in the treatment of advanced metastatic pancreatic cancer (pdac).
PPBT Ratings Summary
PPBT Quant Ranking